...
首页> 外文期刊>American Journal of Cancer Research >PGK1-mediated cancer progression and drug resistance
【24h】

PGK1-mediated cancer progression and drug resistance

机译:PGK1介导的癌症进展和耐药性

获取原文
           

摘要

Phosphoglycerate kinase 1 (PGK1) is an essential enzyme in the aerobic glycolysis pathway. PGK1 catalyzes the reversible transfer of a phosphate group from 1,3-bisphosphoglycerate to ADP and produces 3-phosphoglycerate and ATP. In addition to cell metabolism regulation, PGK1 is involved in multiple biological activities, including angiogenesis, autophagy and DNA repair. Because of its multi-faceted functions, PGK1’s involvement in cancer development is complicated. High intracellular expression of PGK1 leads to tumor cell proliferation. However, high extracellular expression of PGK1 suppresses cancer malignancy through a suppression of angiogenesis. PGK1 is also associated with chemoradiotherapy resistance and poor prognosis of cancer patients. In this manuscript, we summarize the influence of PGK1 and its post-translational modifications on cancer initiation and progression. PGK1-mediated drug resistance and potential small molecule inhibitors targeting PGK1 are discussed for their future clinical applications.
机译:磷酸甘油激酶1(PGK1)是有氧糖醇解途径中的必需酶。 PGK1催化磷酸盐基团的可逆转移从1,3-双磷酸酯至ADP,并产生3-磷酸甘油糖和ATP。除了细胞代谢调节之外,PGK1还参与多种生物活性,包括血管生成,自噬和DNA修复。由于其多面功能,PGK1参与癌症发展是复杂的。 PGK1的高细胞内表达导致肿瘤细胞增殖。然而,通过抑制血管生成,PGK1的高细胞外表达抑制癌症恶性肿瘤。 PGK1还与癌症患者的化学疗法抵抗和差的预后有关。在这一稿件中,我们总结了PGK1的影响及其翻译后对癌症起始和进展的影响。 PGK1介导的耐药性和潜在的小分子抑制剂靶向PGK1的未来临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号